Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress

Abstract

Drug-induced liver injury (DILI) is a serious clinical disease associated with reactive oxygen species (ROS) burst and subsequent inflammatory responses. However, traditional treatments were limited by low efficacy and serious side effects due to the special liver structure. Here, we developed a molybdenum (Mo)-based nanoparticles, EGM NPs, after overall consideration of the pathophysiology of DILI and the advantages of nanodrugs. It demonstrated that EGM NPs treated acetaminophen (APAP)-induced DILI by scavenging ROS and inhibiting inflammation. EGM NPs effectively scavenged various ROS and reduced cell apoptosis at the cellular level. More importantly, EGM NPs can treat APAP-induced DILI in vivo, reducing the levels of liver function indicators in mice with liver injury, scaling down the area of hepatocyte necrosis and successfully inhibiting endoplasmic reticulum (ER) stress in the liver. EGM NPs also showed a certain anti-inflammatory effect by reducing infiltration of macrophages, decreasing pro-inflammatory factors and inhibiting the expression levels of inducible nitric oxide synthase (NOS2) and myeloperoxidase (MPO). Collectively, our findings suggest that EGM NPs-based nanotherapeutic is a novel strategy for the treatment of DILI.

CP-25 exerts a protective effect against ConA-induced hepatitis via regulating inflammation and immune response

“…And other study revealed that CP-25 concentration was higher in liver tissue compared to paeoniflorin due to its elevated oral bioavailability (Zhao et al, 2019). Research supported that there was a positive correlation between ROS elevation and inflammation related pathways activation (Brennan and Gilmore, 2018;Yunrong Yang et al, 2022). And oxidative stress was happened accompanied by excessive ROS levels, which acting as signaling molecules contributing to abnormal cell growth, metastasis, disordered function, as well as enlarged proinflammatory cytokines production, allowing inflammation to progress (Li et al, 2020).…”

Erythrocyte membrane biomimetic EGCG nanoparticles attenuate renal injury induced by diquat through the NF-κB/NLRP3 inflammasome pathway

“…This approach has shown promise in treating cancers, neurodegenerative diseases, and even lessening the occurrence of seizures ( Yang et al, 2020 ; Alrashdi et al, 2023 ). Furthermore, epigallocatechin gallate Mo nanoparticles (EGM NPs) have been shown to effectively protect against drug-induced hepatic damage ( Yang et al, 2022 ).…”